Impact of circulating biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II study

Affiliation auteurs!!!! Error affiliation !!!!
TitreImpact of circulating biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II study
Type de publicationJournal Article
Year of Publication2016
AuteursTijeras-Raballand A., de Gramont A., Chiron M., Bachet J.B, Andre T., Auby D., Desrame J., Baba-Ahmed N., Lecaille C., Lebrun V., Louvet C., Tournigand C., Benner S., Attia M., de Gramont A., Bonnetain F., Chibaudel B.
JournalEUROPEAN JOURNAL OF CANCER
Volume69
PaginationS147
Date PublishedDEC
Type of ArticleMeeting Abstract
ISSN0959-8049
DOI10.1016/S0959-8049(16)33036-2